Efficacy of Galectin-3C in Mouse Model of Metastatic Breast Cancer
Abstract
The goal of this research is to evaluate a potential therapeutic agent for breast cancer based on the lectin galectin-3. The hypothesis to be tested is that therapy with an N-terminally truncated form of galectin-3 (galectin-3C) will be efficacious for inhibition of metastases. The overall purpose of the research is to determine the efficacy, safety and mechanism of action of galectin-3C in treatment of metastatic breast cancer. To this end, recombinant galectin-3 was produced from which galectin-3C was derived by collagenase enzyme digestion and affinity chromatography. For ELISA detection of injected galectin-3C in nude mice, chickens were immunized with galectin-3C but the response yielded only low affinity antibody. An alternative detection strategy was developed by metabolically labeling galectin-3 with 35% methionine prior to collagenase cleavage. The maximum tolerated dose of galectin-3C in nude mice at 5 days was determined to be a minimum of 125 mg)kg without adverse effects.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 1999
- Accession Number
- ADA383096
Entities
People
- Gary A. Jarvis
Organizations
- Northern California Institute for Research and Education